The State Drug Administration has conditional approval of the application for registration of the import of injections by Thedenosumab

recently, the State Drug Administration has conditionally approved the application for registration of the injection of Denosumab, which is not surgically removed or surgically removed for adults and adolescent patients with mature bone development who may cause severe dysfunctionAbout dishu mono-anti-
disco-resistance is a perhuman-based monoclonal monoclonal IgG2 antibody developed by AmgenCompany(http://, and has a high affinity and specificity to soluble, transmembrane human rankLClinicaltrial(http://results have shown that hydrolysis reduces bone absorption and improves bone mass and bone strength, and can therefore be used to treat osteoporosisIn addition, in tumor therapy applications, RANKL's expression in bone metastasis or multiple myeloma increases, resulting in increased bone cell activity and bone dissolution, which can prevent bone dissolution and tumor growth caused by tumor metastasis by inhibiting RANKLTherefore, ground shudre resistance is also of application in tumor therapyIn June 2010, theFDA(http://approved dissonalization (trade name: Prolia) for the treatment of osteoporosis in postmenopausal women, and was later approved for the treatment of osteoporosis in men, and the loss of bone loss due to androgen deprivation treatment for prostate cancer, and the loss of bone loss due to aromatase inhibitor therapy for breast cancer 　　In November 2010, based on the results of three randomized controlled Phase III clinical studies, the FDA approved the bone-related events (SREs) used to treat patients with solid tumor bone metastasis, and then approved the treatment of osteocytoma and malignant hyperhematurioma 　　In addition, Amgen is constantly expanding the new adaptation sofority, such as in January 2018, the FDA approved the treatment of multiple myeloma patients with bone-related events